Handelsbanken Fonder AB Increases Stock Position in Axon Enterprise, Inc $AXON

Key Points

• Handelsbanken Fonder increased its Axon stake by 6.5% in the second quarter, adding 4,261 shares to own 69,798 shares valued at approximately $39.1 million. Institutional investors collectively hold 79.08% of Axon’s outstanding stock.
• Axon posted a quarterly earnings beat, reporting $1.88 in EPS versus $1.84 expected and $904.4 million in revenue versus $876.4 million forecast. Revenue grew 35.3% year over year, helping drive a reported 6.7% stock gain.
• Analysts remain broadly positive, but valuation is a key risk. Axon has a “Moderate Buy” consensus rating and a $730.92 average price target, while its roughly 264 price-to-earnings ratio, margin concerns and recent insider selling could limit further upside.

Handelsbanken Fonder AB boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 6.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,798 shares of the biotechnology company's stock after buying an additional 4,261 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.09% of Axon Enterprise worth $39,129,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AXON. Evergreen Capital Management LLC raised its position in shares of Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after acquiring an additional 15 shares during the period. Synergy Financial Group LTD increased its stake in shares of Axon Enterprise by 1.4% in the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company's stock valued at $996,000 after purchasing an additional 19 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Axon Enterprise by 1.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company's stock valued at $1,350,000 after purchasing an additional 19 shares in the last quarter. Certuity LLC increased its stake in shares of Axon Enterprise by 5.1% in the 4th quarter. Certuity LLC now owns 474 shares of the biotechnology company's stock valued at $269,000 after purchasing an additional 23 shares in the last quarter. Finally, Pure Financial Advisors LLC raised its holdings in Axon Enterprise by 6.7% in the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company's stock worth $207,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Earnings beat supports the rally: Axon reported quarterly earnings of $1.88 per share versus the $1.84 consensus estimate, while revenue of $904.4 million exceeded expectations of $876.4 million. Revenue increased 35.3% year over year, reinforcing the company’s strong demand across connected public-safety hardware and software. Axon Jumps After Earnings Beat and Analyst Target Hikes
• Positive Sentiment: Analyst support and future catalysts: Analyst target increases and the post-earnings rebound have improved sentiment, with investors awaiting the next potential growth catalyst. The company’s expanding product ecosystem and strong top-line growth remain central to the bullish case. Analyst Target Hikes and Next Catalyst
• Neutral Sentiment: Short-interest data provides no signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the figures show no meaningful short position, they are unlikely to explain the stock’s move or provide useful evidence of future buying pressure.
• Negative Sentiment: Valuation remains demanding: Commentary highlights Axon’s strong growth but also its high valuation, while another analyst downgraded the stock and suggested taking some profits. The shares trade at a very high earnings multiple, leaving them vulnerable if growth or profitability disappoints. Axon Rating Downgrade
• Negative Sentiment: Margin pressure and insider selling temper enthusiasm: Investors remain focused on memory costs and counter-drone hardware expenses, which may constrain margins as Axon invests for growth. CEO Patrick W. Smith also sold approximately $5.5 million of shares under a pre-arranged Rule 10b5-1 plan, though the sale represented only about 0.33% of his holdings.

Axon Enterprise Trading Up 6.7%

AXON stock opened at $636.31 on Wednesday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $824.66. The stock has a market cap of $51.69 billion, a price-to-earnings ratio of 264.03, a PEG ratio of 12.17 and a beta of 1.39. The business's 50-day moving average is $519.11 and its 200 day moving average is $473.46.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. During the same period in the previous year, the business earned $2.12 EPS. Axon Enterprise's quarterly revenue was up 35.3% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Piper Sandler increased their price target on Axon Enterprise from $724.00 to $732.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Royal Bank Of Canada restated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Weiss Ratings reiterated a "hold (c-)" rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Needham & Company LLC reiterated a "buy" rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Finally, Zacks Research cut shares of Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Axon Enterprise presently has a consensus rating of "Moderate Buy" and a consensus target price of $730.92.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 564 shares of the firm's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $478.97, for a total value of $270,139.08. Following the transaction, the director owned 3,632 shares in the company, valued at approximately $1,739,619.04. This trade represents a 13.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joshua Isner sold 13,000 shares of the firm's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the transaction, the president owned 169,125 shares in the company, valued at $82,609,106.25. The trade was a 7.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 68,989 shares of company stock valued at $36,016,932. Insiders own 4.20% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source